

# SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients

**Yuxin Chen**

yuxin.chen@nju.edu.cn

Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School

**Tiantian Zhao**

Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine

**Lin Chen**

Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University

**Guozhi Jiang**

Nanjing Important Science & Technology Specific Projects (2021-11005), Scientific Research Project of Jiangsu Health Commission (M2022013), Clinical Trials from the Affiliated Drum Tower Hospital, M

**Yu Geng**

Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine

**Wanting Li**

Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University

**Shengxia Yin**

Institute of Viruses and Infectious Diseases

**Yue Tao**

Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University

**Jun Ni**

Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University

**Qiuhan Lu**

School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University

**Mingzhe Ning**

Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University

**Chao Wu**

Nanjing Drum Tower Hospital, Nanjing University Medical School

---

**Article**

**Keywords:** Omicron BA.5, CoronaVac, IgA, B cells, T cells, immune imprinting

**Posted Date:** September 29th, 2023

**DOI:** <https://doi.org/10.21203/rs.3.rs-3325813/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Additional Declarations:** (Not answered)

---

**Version of Record:** A version of this preprint was published at mBio on March 8th, 2024. See the published version at <https://doi.org/10.1128/mbio.02407-23>.

# Abstract

The inactivated whole-virion vaccine, CoronaVac, is one of the most widely used coronavirus disease 2019 (COVID-19) vaccines worldwide. There is a paucity of data indicating the durability of the immune response and the impact of immune imprinting induced by CoronaVac upon Omicron breakthrough infection. In this prospective cohort study, 41 triple-dose CoronaVac recipients and 14 unvaccinated individuals were recruited and the anti-SARS-CoV-2 adaptive responses were analyzed before and post Omicron BA.5 infection. Twelve months after the third CoronaVac vaccination, spike-specific antibody and cellular responses were detectable in most vaccinees. BA.5 infection significantly augmented the magnitude, cross-reactivity and durability of serum neutralization activities, Fc-mediated phagocytosis, and nasal spike-specific IgA responses, memory B cells, memory CD4 + T cells, and memory CD8 + T cells for both the ancestral strain and Omicron subvariants, compared to unvaccinated individuals. Notably, the increment in BA.5-specific immunity after breakthrough infection was consistently higher than for the ancestral strain, suggesting no evidence of immune imprinting. Immune landscape analyses showed vaccinated individuals have better synchronization of multiple immune components than unvaccinated individuals upon heterologous SARS-CoV-2 infection. Our data provides detailed insight into the protective role of inactivated COVID-19 vaccine in shaping humoral and cellular immune responses to heterologous Omicron infection.

## Trial registration

ClinicalTrials.gov NCT05680896

## Introduction

Three years after the coronavirus disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remarkable collaborative efforts have been made to mitigate the pandemic. The worldwide COVID-19 vaccination campaign demonstrated outstanding effects on reducing the severity of SARS-CoV-2 infection.(ref.1–3) CoronaVac, a whole-virion inactivated vaccine produced by Sinovac, is the most widely offered COVID-19 vaccine globally. Although the diminished immunity and emergence of new viral variants have fueled an increase in breakthrough infections, the protection efficacy of the triple-dose inactivated vaccine against BA.2 infection was 74% against pneumonia and 93% against severe COVID-19. (ref.4)

Understanding the immunological mechanism for this vaccine-derived protection has important implications for future pandemic preparedness. In a prospective vaccine cohort, we previously analyzed the longitudinal immune responses elicited by the triple-dose inactivated COVID-19 vaccine up to 2 months. (ref.2,5–7) Since the adjustment of the public health policy for containing COVID-19 in China in December 2022, SARS-CoV-2 Omicron variant wave resulted in large-scale breakthrough infection. In this study, we aimed to address two equally important issues. First, we examined whether CoronaVac-induced immune memory could still be effectively recalled up to 12 months after the third booster dose, especially

the Omicron variant is associated with a marked capability to evade humoral immunity resulting from either prior natural infection or vaccination(ref.8,9). Secondly, there are rising concerns regarding the immune imprinting induced by ancestral strain-based vaccinations, which might compromise the antibody response to Omicron-based boosters.

Herein, we investigated these questions by measuring SARS-CoV-2-specific dynamic immune trajectories including antibody responses, Fc-mediated effector function, neutralization capacity, and cellular responses after Omicron BA.5 infection among recipients of triple-dose CoronaVac and unvaccinated individuals. Our data provide detailed insight into the favorable role of pre-existing immune responses elicited by triple-dose CoronaVac, which are capable of potentially recalling SARS-CoV-2 immunity with cross-recognition to Omicron variants.

## **Materials and Methods**

### **Study design and Cohort selection**

The purpose of this prospective, observational study (NCT05680896) was to directly compare the humoral and cellular immune response among triple CoronaVac vaccinated individuals or unvaccinated individuals who were subsequently contracted Omicron BA.5 infection during the omicron wave last Dec in China. Serum and nasal samples were collected from participants for the subsequent enzyme-linked immunosorbent (ELISA) assay, pseudovirus neutralization assay, antibody dependent cellular phagocytosis, as well as flow-cytometry based cellular analysis.

Healthcare workers at Nanjing Drum Tower Hospital were recruited and enrolled in the study belonging to two groups: vaccinated and unvaccinated individuals. Written informed consent was obtained and study approval was obtained from the ethics committee from Nanjing Drum Tower Hospital (2021-034-01 and 20222-746). The vaccinated group received the first two doses of CoronaVac in Feb 2021 and the third dose of CoronaVac in Nov 2022, while the unvaccinated individuals did not receive any COVID-19 vaccine prior to Omicron BA.5 infection. Both groups had PCR confirmed diagnosis of COVID-19 during the recent omicron wave from Dec 2022 and Jan 2023 and the infected viral sequence was further confirmed by next-generation sequencing. For vaccinated participants, baseline samples were collected at 12-months post the third CoronaVac immunization.

### **Measurement of serum and nasal SARS-CoV-2 spike-specific humoral responses**

Serum or nasal swabs for immunological assessments were taken at three different time points, including 12 months post the third dose before BA.5 infection, 2 weeks and 20 weeks post BA.5 infection. Antigen-specific serological and nasal swab antibodies against SARS-CoV-2 were determined by an in-house enzyme-linked immunosorbent assay (ELISA), as previously described(ref.2,10). Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent neutrophil phagocytosis (ADNP) were described in the previously study.(ref.7) Pseudovirus neutralization assay was performed using lentivirus-

based SARS-CoV-2 pseudoviruses were provided by Vazyme Biotech Co., Ltd, as previously described. (ref.2,11)

## Antigen-specific Measurement of Cellular Analyses

The biotinylated ectodomain of spike protein was fluorescently labeled to identify SARS-CoV-2 specific circulating B cells and memory B cells. The detailed approach has been described in previous studies. (ref.2,5) To measure antigen specific circulating and memory CD4<sup>+</sup>, CD8<sup>+</sup> T cells and Tfh cells, activation-induced marker (AIM) assay were performed as previous described. (ref.2,5)

# Results

## Study cohort and study design

We recruited a total of 55 participants, including 41 recipients of triple-dose CoronaVac and 14 individuals who were not vaccinated against COVID-19 (Fig. 1a). Omicron BA.5 infection was confirmed in all individuals by next-generation sequencing. The demographic and clinical characteristics of the cohort are summarized in Fig. 1b. Notably, 3 (23.1%) out of 14 unvaccinated individuals, but none of vaccinated individuals, developed severe COVID-19 disease. Sampling at 12 months after the third booster dose (T0), as well as at 2 weeks (T1) and 20 weeks (T2) after SARS-CoV-2 infection, allowed the immune trajectories to be measured to assess the establishment and maintenance of hybrid immunity. Simultaneous serum, peripheral blood mononuclear cell, and nasal swab samples were collected from each of the participants.

## Breakthrough infection enhanced the magnitude and durability of humoral antibody responses

Since antibodies are considered as the correlates of protection against SARS-CoV-2 infection,(ref.12) we investigated the magnitude of variant-specific immunoglobulin (Ig)G and IgA binding in the serum. Baseline sera at T0 exhibited an ancestral spike-specific binding geometric median titer (GMT) of 1,332, while the GMT specific to BA.5 and XBB.1.5 was 1,218 and 943, respectively (Fig. 2a). The convalescent serum from vaccinated individuals at T1 showed an increment of 672-fold for anti-ancestral spike IgG. The fold elevation in anti-BA.5, anti-XBB.1, and anti-XBB.1.5 spike IgG titers was 1164-fold, 9928-fold, and 234-fold, respectively. Compared to unvaccinated individuals, vaccinated individuals exhibited a considerably higher ancestral spike-specific IgG titer and BA.5 spike-specific IgG titer. Similar patterns were also observed for the XBB.1, XBB.1.5, and Delta spike-specific IgG titers.

We assessed the durability of the binding antibody titers at T2. Compared with the unvaccinated controls, vaccinated individuals retained a significantly greater anti-spike IgG titer, not only specific to the ancestral spike, but also to the BA.5, XBB.1, and XBB.1.5, and Delta spike. Meanwhile, serological SARS-CoV-2-specific IgA responses were also detected (Fig. 2b). After BA.5 infection, 40 of 41 fully vaccinated individuals (97%) were IgA-positive for the ancestral spike, and 100% and 97% were IgA-positive for the BA.5 and XBB.1.5 spikes, respectively. 7 of 14 unvaccinated individuals (50%) were IgA-positive for the

ancestral spike, and 62% and 46% were IgA-positive for the BA.5 and XBB.1.5 spikes, respectively. Compared to T0, BA.5 infection induced strong recall responses in vaccinated individuals at T1, leading to 1,547-fold, 299-fold and 44-fold increased IgA titers specific to the ancestral, BA.5 and XBB.1.5 strains, respectively. Consistently, vaccinated individuals showed significant enhancement of spike-specific IgA responses across the variants compared with unvaccinated individuals. Vaccinated individuals had significantly higher BA.5 spike and Delta spike IgA responses at T2.

### **Triple-dose CoronaVac expanded nasal IgA and IgG antibody titers after acquired BA.5 infection**

Recent evidence has demonstrated mucosal IgA is protective against Omicron infection.(ref.13) We detected a higher nasal anti-spike IgA titer specific to BA.5, Delta, and XBB.1 in the vaccinated group than in the unvaccinated group (**Fig. 2c**). A similar trend was detected for nasal IgG responses. However, such differences were less obvious at T2.

### **Breakthrough infection induced stronger antibody-dependent cellular and neutrophil phagocytosis than natural BA.5 infection**

Fc-mediated effector functions have been demonstrated to reduce the severity of disease rather than reducing transmission.(ref.14) The vaccinated group had substantially elevated antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent neutrophil phagocytosis (ADNP) compared with unvaccinated controls (**Fig. 2e**). Specifically, plasma samples from triple-dose CoronaVac recipients showed higher ADCP responses specific to the ancestral (2.29-fold), BA.5 (1.91-fold), and XBB.1.5 (1.79-fold) spikes than unvaccinated controls. Minimal ADNP activity was detected among unvaccinated individuals, while the vaccinated individuals had considerably enhanced ancestral (1.75-fold), BA.5 (2.76-fold), and XBB.1.5 (2.44-fold higher) spike ADNP activity.

### **Breakthrough infection enhanced the breadth and potency of neutralization activity**

Omicron subvariants, especially XBB subvariants, are considered to be highly resistant to vaccines and infection-induced humoral immunity.(ref.15,16) The geometric mean 50% neutralizing antibody titers (NT<sub>50</sub> GMTs) for the ancestral, BA.5, BF.7, BQ1.1, XBB, XBB.1, and XBB.1.5 strains in the vaccinated group were 2,691.8, 955.8, 1,117.5, 785.9, 190.8, 121.4, and 95.9, respectively. The NT<sub>50</sub> GMTs of the unvaccinated group against the ancestral (46.1; 58.4-fold, p < 0.0001), BA.5 (158.6; 6.0-fold, p = 0.002), BF.7 (177.4; 6.3-fold, p = 0.003), BQ1.1 (279.0; 2.8-fold, p = 0.032), XBB (140.1; 1.4-fold, p = 0.486), XBB.1 (96.5; 1.3-fold, p = 0.044), and XBB.1.5 (41.9; 2.3-fold, p = 0.023) strains were significantly compromised (**Fig. 2f**). The largest difference was observed for neutralization activity against the ancestral strain, whereas the smallest difference was observed for the XBB.1 strain between vaccinated and unvaccinated individuals.

### **BA.5 infection enhanced cross-reactive spike-specific B cell responses that persisted for up to 20 weeks**

We previously showed that while antibodies decline over time, B cells persist and cross-react with SARS-CoV-2 variants of concern to some degree.(ref.2,5) Therefore, we evaluated the magnitude and cross-reactivity of the antigen-specific B cell response via flow cytometric numeration of B cells stained with differentially labeled ancestral, BA.1, BA.2, and BA.5 spike proteins (**Fig. 3a**). At baseline, ancestral and BA.5 spike reactive B cells were detectable in 23 (79%) and 17 (59%) of 29 participants, comprising a median of 0.090% and 0.047% of the total B cells, respectively, among vaccinated individuals. Minimal ancestral spike-specific B cells (0.030%) were detected in unvaccinated controls (**Fig. 3a**).

Correspondingly, BA.5 spike-specific B cells increased from 0.047% of the total B cells at baseline to 0.43% at 2 weeks, and slightly decreased to 0.22% at 20 weeks after BA.5 infection. In contrast, BA.5 infected unvaccinated individuals had significantly lower levels of ancestral (1.67-fold), BA.5 (1.79-fold), and BA.1 (2.14-fold) spike-specific B cells at T1 compared with vaccinated individuals (**Fig. 3b**). Twenty weeks after BA.5 infection, unvaccinated individuals still exhibited a lower proportion of spike-reactive B cells than the vaccinated group across the tested Omicron subvariants, including BA.5 (1.91-fold), BA.1 (2.19-fold), and BA.2 (1.95-fold).

The proportion of spike-specific memory B cells among the total memory B cells was also analyzed (**Fig. 3c**). Triple-dose CoronaVac recipients showed a median of 0.076%, 0.048%, 0.055%, and 0.041% memory B cells specific to ancestral, BA.1, BA.2, and BA.5, respectively, even at 12 months after the third booster vaccination. Memory B cells were absent in unvaccinated individuals at T0. BA.5 breakthrough infection expanded cross-reactive spike-specific memory B cells. At T1, compared to unvaccinated controls, vaccinated individuals showed remarkably higher levels of memory B cells specific to the ancestral (0.17% vs. 0.26%), BA.5 (0.25% vs. 0.43%), BA.1 (0.17% vs. 0.38%), and BA.2 (0.18% vs. 0.20%) strains (**Fig. 3d**). At T2, vaccinated individuals still maintained higher levels of spike-specific memory B cells than unvaccinated individuals, but the difference was not statistically different except for BA.5-specific memory B cells.

### **Vaccination enabled activation of circulating follicular helper T (cTfh) cells and expansion of memory cTfh cells upon BA.5 breakthrough infection**

To this end, we tracked and depicted the frequency of spike-specific circulating T follicular helper (Tfh) cells, a counterpart to GC Tfh cells to support antibody secretion. (ref.18) BA.5 infection expanded ancestral-specific cTfh cells from 0.057% at baseline to 0.139% at T1, and BA.5 spike-specific cTfh cells from 0.050% at baseline to 0.203% at T1, among vaccinated individuals (**Fig. 3e**). The frequency of spike-specific cTfh cells across SARS-CoV-2 variants was 2.04–19.82-fold higher in vaccinated individuals than in unvaccinated individuals. In particular, the percentage of BA.5-specific cTfh cells in the vaccinated group was 0.203% and 0.093% at T1 and T2, respectively (5.23-fold and 6.84-fold higher than in unvaccinated individuals) (**Fig. 3f**).

At T0, despite being 12 months after the third dose of CoronaVac, vaccinated individuals not only showed a detectable level of spike-specific memory cTfh cell responses (**Fig. 3g**). After BA.5 infection, there was a

trend toward slightly higher spike-specific memory cTfh cells in vaccinated individuals than in unvaccinated individuals, but no significant difference was observed (**Fig. 3h**).

### **BA.5 infection enhanced cross-reactive memory T cells among recipients of triple-dose CoronaVac**

T cells contribute to the defense against viral infections by orchestrating antibody production and cytotoxic killing of infected cells.(ref.19) Previously, we observed that CoronaVac induced durable, cross-reactive T cell responses.(ref.2,5) Given their importance, we examined whether BA.5 breakthrough infection could quickly recall and expand ancestral- and BA.5-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses. The data show that triple-dose CoronaVac recipients still showed detectable CD4<sup>+</sup> T cells with a median frequency of 0.026% (**Fig. 4a**) and CD8<sup>+</sup> T cells with a median frequency of 0.035% (**Fig. 4b**). In contrast, few spike-specific CD4<sup>+</sup> or CD8<sup>+</sup> T cell responses were detected in unvaccinated individuals. At T1, BA.5 breakthrough infection effectively expanded both CD4<sup>+</sup> T cell (3.73-fold) and CD8<sup>+</sup> T cell (5.45-fold) responses specific to the BA.5 spike (**Fig. 4a, 4e**). Similar trends were also observed in the T cell responses across the ancestral strain and the Omicron subvariants at T2.

We also longitudinally measured the frequency of specific memory T cell responses. Compared with the corresponding baseline samples, BA.5 breakthrough infection led to augmented BA.5 spike-specific memory CD4<sup>+</sup> T cell (5.24-fold) and memory CD8<sup>+</sup> T cell (18.52-fold) responses at T1 (**Fig. 4c, 4g**). Interestingly, there was a trend toward a slightly higher frequency of specific memory CD4<sup>+</sup> T cell responses in vaccinated individuals than in unvaccinated controls, but without significant differences (**Fig. 4d**). In contrast, compared with unvaccinated controls, vaccinated individuals showed substantially higher levels of ancestral (0.504% vs. 0.139%), BA.5 (0.500% vs. 0.210%), BA.1 (0.462% vs. 0.091%), and BA.2 (0.422% vs. 0.216%) spike-specific CD8<sup>+</sup> memory T cell responses (**Fig. 4g, 4h**).

### **The increase in BA.5-specific immune responses after breakthrough infection was consistently higher than for the ancestral strain**

Immune imprinting induced by ancestral strain-based vaccination might compromise the antibody response to Omicron-based boosters.(ref.8,9) Therefore, we compared the increases in the ancestral- and BA.5-specific immune responses in vaccinated individuals (**Fig. 5**). Notably, the increase from T0 to T1 in the BA.5 spike-specific IgG response was substantially higher than for the ancestral spike (**Fig. 5a**). Similarly, the majority of BA.5-specific immune parameters, including B cells, memory B cells, memory Tfh cells, CD4<sup>+</sup> T cells, memory CD4<sup>+</sup> T cells, and memory CD8<sup>+</sup> T cells, displayed substantially greater fold changes than those specific to the ancestral strain at T1 (**Fig. 5b–c**). Nevertheless, the enhanced increase in the BA.5-specific immune response was not observed at T2 (**Fig. 5d–f**).

### **Distinct immune trajectories in breakthrough-infected individuals versus naturally infected individuals**

The BA.5 infected vaccinated group exhibited remarkable divergence in SARS-CoV-2-specific immune responses compared with the unvaccinated group. Further exploratory analyses were performed to gain a



more detailed understanding of their fundamental differences. Following centering and scaling, hierarchical clustering of the participants revealed that vaccinated samples clustered away from the unvaccinated samples (Fig. 6a), highlighting the potent multicomponent immune memory induced by CoronaVac, even up to 12 months after the third CoronaVac dose. A multivariate partial least squares-discriminant analysis was performed across the vaccinated group and the unvaccinated group at the peak immune response after breakthrough infection (Fig. 6b). Vaccinated individuals could be perfectly separated from unvaccinated individuals. Notably, the immune profiles of participants in the vaccinated group exhibited selective enrichment of ancestral-specific ADCP, XBB.1-specific ADNP, BA.5-specific Tfh cells, and BA.1-specific B cells and memory B cells (Fig. 6c).

We also performed correlation analyses for the measured immune parameters, including antibody binding, neutralization activity, B cells, CD4<sup>+</sup> cells, CD8<sup>+</sup> cells, and Tfh cell responses, as well as their memory subsets, among the vaccinated group and the unvaccinated group. In the vaccinated group, we observed a moderate-to-low degree of correlation among the parameters defining the antibody response and among the parameters defining T cell responses. Further, binding antibody responses were positively correlated with the CD4<sup>+</sup> T cell response and the corresponding memory subsets (Fig. 6d). In the unvaccinated group, we observed a strong or moderate degree of correlation within the antibody compartment and within the T cell compartment. Nevertheless, a considerable proportion of inverse correlations were identified between antibodies and CD8<sup>+</sup> memory T cells and cTfh cells, as well as between the CD4<sup>+</sup> T cell response and memory cTfh cells (Fig. 6e).

Additionally, we investigated the correlation between systemic and mucosal humoral immunity. BA.5-infected individuals in the vaccinated group demonstrated a significant positive correlation between serum-neutralizing activity and nasal IgA binding as well as IgG responses. Further, strong positive correlations were identified within nasal IgA and IgG binding specific to SARS-CoV-2 variant spike antigens (Fig. 6f). Surprisingly, for previously unvaccinated individuals, serum neutralizing activity was negatively correlated with nasal binding antibody titers after BA.5 infection. Additionally, few cross-correlations were identified among the parameters of the nasal IgG and IgA binding antibodies (Fig. 6g). Collectively, our data highlight that vaccinated individuals have better synchronization of multiple immune components than unvaccinated individuals upon heterologous SARS-CoV-2 infection.

## Discussion

The inactivated whole-virion vaccine CoronaVac is one of the most widely used COVID-19 vaccines worldwide.(ref.20) Although there has been continual evolution of viral variants, which have managed to evade antibody responses to varying degrees, triple-dose CoronaVac has retained more effectiveness against severe disease than against overall infection.(ref.21) In this study, we provide strong evidence of the robust immune memory responses to ancestral and Omicron subvariants after triple-dose CoronaVac, which are maintained 12 months after the last dose. We also performed head-to-head comparisons of immune responses among vaccinated individuals versus unvaccinated individuals. When considered

alongside the risk of severe infection and the long-term consequences of infection, our findings have important implications for vaccine policy.

Understanding the durability of the protection conferred by SARS-CoV-2 vaccination is of utmost importance to guide COVID-19 mitigation policies worldwide. For the first time, our longitudinal follow-up over 12 months after the third CoronaVac dose demonstrated the durability and long-term maintenance of SARS-CoV-2 circulating B cells and CD4<sup>+</sup> and CD8<sup>+</sup> memory T cells.

As most people are vaccinated against the ancestral SARS-CoV-2 strain, immune imprinting presents a major challenge to the performance of updated boosters. It has been suggested that boosting with a variant that is antigenically distinct from the ancestral strain would recall pre-existing memory B cells induced by the ancestral strain, preventing the generation of humoral immune responses targeting new variants.(ref.23) Intriguingly, our results did not show strong evidence of antigenic sin in the antibody responses after Omicron infection. This might be due to the relatively longer interval between the last booster dose and breakthrough infection than in previous reports, which warrants further investigation. (ref.9,24) Additionally, we showed that the increases in BA.5-specific memory cellular responses, including memory B cells, Tfh cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells, after breakthrough infection were consistently higher than those of the ancestral strain. This finding aligns with recent evidence showing that either SARS-CoV-2 Omicron boosting or Omicron breakthrough infection not only triggers rapid memory cellular responses but also induces *de novo* B(ref.25)and T cell(ref.26) responses. In addition, we(ref.2,5) and others(ref.28) have shown that T cell responses are less affected by viral variants than antibodies, which is likely due to the broader range of epitopes available to T cells compared with antibodies, where protective responses are more focused.

Further support for the protective role of triple-dose CoronaVac comes from our observation that hybrid immunity strengthens and broadens antibody responses, mucosal immunity, and cellular immunity, providing the most sustained protection. Despite of substantial evidence highlighting the remarkable enhancement of serological and cellular responses elicited by hybrid immunity, our data firstly demonstrate that a larger proportion of breakthrough-infected individuals harbored nasal spike-specific IgA responses than unvaccinated individuals.

Our study has important implications for the vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging SARS-CoV-2. In the absence of vaccination, BA.5 infection-elicited humoral responses showed remarkably reduced serum neutralization activity against Omicron subvariants, and barely neutralize the ancestral strain. Additionally, BA.5 infection only induce modest level of nasal IgA responses. Furthermore, Fc-mediated phagocytosis and mucosal immunity were not effectively induced in BA.5 infected unvaccinated individuals. Taken together, the modest immune responses in BA.5-infected unvaccinated individuals leave this unvaccinated group at risk of being reinfected with Omicron subvariants.

Our results also provide an immune landscape of hybrid immunity elicited by BA.5 infection in triple-vaccinated versus unvaccinated individuals. Vaccination with triple-dose CoronaVac effectively evoked higher-quality immune responses characterized by convergent development of humoral and cellular immune compartments, as well as collaborative systemic and mucosal antibody compartments. Machine learning analysis showed that vaccinated individuals generated potent immune responses involving ADCP, ADNP, Tfh cells, activated B cells, and memory B cells, compared to unvaccinated donors. Omicron BA.5 infection might not be sufficient to trigger cross-reactive humoral and cellular responses.

This study has some limitations that should be noted. First, the participants in our cohort were generally young; older individuals were not included. Secondly, we used peptide stimulation to measure T and B cell responses to SARS-CoV-2 spike proteins. The use of conjugated peptide major histocompatibility complex (pMHC) multimers might result in the sensitive detection of antigen-specific T cells at a higher resolution.

In summary, we have shown that triple-dose CoronaVac augments antibody, mucosal, and cellular responses that are potent, durable, and cross-reactive to Omicron subvariants. This study sheds light on the dynamics human adaptive immunity to SARS-CoV-2 Omicron subvariants in a highly vaccinated population with inactivated COVID-19 vaccines.

## **Declarations**

### **Contributors**

Y.C., C.W. and M.N. contributed to study design, consultation and funding. M.N., Y.C., T.Z. and C.L. contributed to study design, experiments, manuscript writing and revision; Y.G, L.C., W.L. and S.Y. contributed to experiments, data analysis, bioinformatics analysis and figure generation; S.Y. and Y.T. contributed to experiments; J.N. and M.Z. contributed to bioinformatics analysis; Q.L., G.Z. and G.J. contributed to critical technical supports and reagents; M.Z. and W.L. contributed to consultation; All authors have read and approved the article.

### **Data sharing statement**

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

### **Conflict of Interest**

All authors declare no competing interests.

### **Acknowledgments**

We are grateful to all the participants who participated in this study.

Funding: This study was supported by the National Natural Science Foundation of China (92269118, 92269205), Nanjing Important Science & Technology Specific Projects (2021-11005), Scientific Research Project of Jiangsu Health Commission (M2022013), Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2021-LCYJ-PY-9), and Jiangsu graduate practice innovation project (JX22013929).

### Data availability

R package 'ropls' version 1.20.043 and "glmnet" version 4.0.244 and the systemseRology R package (v.1.1) (<https://github.com/LoosC/systemsseRology>) were used for analysis.

The correlation analysis was presented using ChiPlot ([https://www.chiplot.online/correlation\\_heatmap.html](https://www.chiplot.online/correlation_heatmap.html)).

### Ethics approval and consent to participate:

Written informed consent was obtained at the time of enrollment and study approval was obtained from the ethics committee of institutional review board from Nanjing Drum Tower Hospital (2021-034-01 and 20222-746).


## References

1. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet (London, England)* 2022; **399**(10328): 924-44.
2. Chen Y, Yin S, Tong X, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2022; **28**(3): 410-8.
3. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. *JAMA network open* 2022; **5**(8): e2228900.
4. Tang L, Wang FZ, Rodewald LE, et al. Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study. *The Journal of infectious diseases* 2023.
5. Chen Y, Chen L, Yin S, et al. The Third dose of CoronaVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. *Emerging microbes & infections* 2022; **11**(1): 1524-36.
6. Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. *The Lancet Infectious diseases* 2021; **21**(8): 1071-2.

7. Wang L, Li C, Li W, et al. Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities. *Emerging microbes & infections* 2023; **12**(2): 2225640.
8. Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. *Nature* 2023; **614**(7948): 521-9.
9. Ju B, Fan Q, Wang M, et al. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. *Nature communications* 2022; **13**(1): 7120.
10. Li T, Han X, Gu C, et al. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. *Nature communications* 2021; **12**(1): 6304.
11. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nature biotechnology* 2020; **38**(9): 1073-8.
12. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science (New York, NY)* 2022; **375**(6576): 43-50.
13. Havervall S, Marking U, Svensson J, et al. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. *The New England journal of medicine* 2022; **387**(14): 1333-6.
14. Zhang A, Stacey HD, D'Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. *Nature reviews Immunology* 2023; **23**(6): 381-96.
15. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell* 2023; **186**(2): 279-86.e8.
16. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. *Nature* 2022; **608**(7923): 593-602.
17. Terreri S, Piano Mortari E, Vinci MR, et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. *Cell host & microbe* 2022; **30**(3): 400-8.e4.
18. Walker LSK. The link between circulating follicular helper T cells and autoimmunity. *Nature reviews Immunology* 2022; **22**(9): 567-75.
19. Moss P. The T cell immune response against SARS-CoV-2. *Nature immunology* 2022; **23**(2): 186-93.
20. WHO. COVID-19 vaccines. 2022. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines> (accessed May 20).
21. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. *The Lancet Infectious diseases* 2022; **22**(10): 1435-43.
22. Mok CKP, Chen C, Zhao S, et al. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. *The Lancet Microbe* 2023; **4**(6): e418-e30.

23. Wang Q, Bowen A, Tam AR, et al. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. *The Lancet Infectious diseases* 2023; **23**(5): 527-8.
24. Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. *Science (New York, NY)* 2022; **377**(6603): eabq1841.
25. Alsoussi WB, Malladi SK, Zhou JQ, et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. *Nature* 2023; **617**(7961): 592-8.
26. Koutsakos M, Reynaldi A, Lee WS, et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. *Immunity* 2023; **56**(4): 879-92.e4.
27. Marking U, Bladh O, Havervall S, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. *The Lancet Infectious diseases* 2023; **23**(2): 150-2.
28. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *The Lancet Infectious diseases* 2022; **22**(6): 781-90.

## Figures



b

Variables(n[%] or median[IQR])	Vaccinated (n=41)	Unvaccinated (n=14)
<b>Sex</b>		
Male	18 (43.9%)	7 (50.0%)
Female	23 (56.1%)	7 (50.0%)
<b>Age</b>	42.0 (30.0, 56.0)	45.0 (31.5, 58.5)
<b>Vaccine history</b>	3 x CoronaVac	0
<b>Last vaccination time</b>	Nov 2021	NA
<b>Disease onset time</b>	Dec 2022	Dec 2022-Jan 2023
<b>Sample collection T0</b>	Nov 2022	Nov 2022
<b>Days post infection</b>		
T1	18 (15, 21)	14 (13.5, 15)
T2	146.5 (144.8, 150.0)	127.5 (113.8, 140.3)
<b>Disease severity</b>		
Severe	0 (0%)	3 (23.1%)
Non-severe	41 (100%)	11 (76.9%)

Figure 1

**Study design and demographic characteristics of our cohort.** (a) Study design of vaccinated individuals and unvaccinated individuals with Omicron BA.5 infection. Vaccination, infection and blood draw timeline were also noted. (b) The demographic and clinical characteristics of the study cohort.

Figure 2




Figure 2

**Omicron BA.5 infection enhanced serum and mucosal humoral response in triple CoronaVac vaccinated individuals.** (a-d) Enzyme-linked immunosorbent assay (ELISA) measurement for serum anti-spike IgG titer (a), serum anti-spike IgA titer (b), nasal anti-spike IgG titer (c) and nasal anti-spike IgA titer (d) at different time points, including 12-month after the third dose vaccination (T0), 2 weeks (T1) and 20 weeks (T2) post BA.5 infection. (e) Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent neutrophil phagocytosis (ADNP) specific to spike protein of ancestral, BA.5 and XBB.1.5 at T1 were also analyzed. (f) Serum titers that achieved 50% pseudovirus neutralization (ID<sub>50</sub>) of seven SARS-CoV-2 variants at T1 timepoint. Data points on the bar graph represent individual titer and the line indicates geometric mean titer (GMT).



Figure 3




Figure 3

**BA.5 infection enhanced cross-reactive spike specific B cell responses and T follicular helper (Tfh) cells that persist up to five months in vaccinated individuals. (a, c, e, g)** The dynamic frequency of spike-specific B cells **(a)**, memory B cells **(c)**, activated Tfh cells **(e)** and memory Tfh cells **(g)** specific to ancestral spike, BA.1 spike BA.2 spike and BA.5 spike at T0, T1 and T2 timepoint. Values above the symbols denote the median, and the percentage of positive responders were also noted. **(b, d, f, h)** The comparison of SARS-CoV-2 specific B cells **(b)**, memory B cells **(d)**, activated Tfh cells **(f)** and memory Tfh cells **(h)** between vaccinated and unvaccinated individuals at T0, T1, and T2 timepoint. Fold change of spike-specific B cells between two groups at three timepoints. Data are shown as the fold-change between vaccinated versus unvaccinated donors. Dotted lines indicated the limit of detection (LOD) for the assay. Single comparisons variables between two groups were performed using the Mann-Whitney U test. Multiple comparisons of specific and specific memory B cell responses at three timepoints were performed using the Friedman’s one-way ANOVA with LSD. \* indicates  $p < 0.05$ , \*\* indicates  $p < 0.01$ , \*\*\* indicates  $p < 0.001$ , \*\*\*\* indicates  $p < 0.0001$ ; ns indicates no significant difference.

Figure 4




Figure 4

BA.5 infection enhanced cross-reactive memory T cells among previously triple CoronaVac vaccinees. (a, c, e, g) The dynamic change of activated CD4+ T cells (a), memory CD4+ T cells (c), activated CD8+ T cells (e) and memory CD8+ T cells (g) specific to ancestral, BA.1, BA.2 and BA.5 spike in vaccinated and unvaccinated groups at T0, T1, T2 timepoint. Values above the symbols denote the median and the percentage of positive responders were also noted. (b, d, f, h) The comparison of SARS-CoV-2 specific activated CD4+ T cells (b), memory CD4+ T cells (d), activated CD8+ T cells (f) and memory CD8+ T cells (h) between vaccinated and unvaccinated individuals at T0, T1, and T2 timepoint. Data are shown as the fold-change between vaccinated versus unvaccinated donors. Single comparisons variables between groups were performed using the Mann-Whitney U test. Multiple comparisons of specific T cell responses of three timpoints were performed using the Friedman's one-way ANOVA with LSD. Dotted lines indicated the limit of detection (LOD) for the assay. Bars represented median value.  $p < 0.05$  was considered to be statistically significant. \* indicates  $p < 0.05$ , \*\* indicates  $p < 0.01$ , \*\*\* indicates  $p < 0.001$ , \*\*\*\* indicates  $p < 0.0001$ . ns indicates no significant difference.

Figure 5




Figure 5

**Increase fold of BA.5 specific immune responses post breakthrough infection were consistently higher than those of ancestral strain. (a-c)** Fold change of of serum anti-spike IgG and IgA (a) and B cells, memoryB cells, Tfh and memory Tfh cells (b), CD4+T cells, memory CD4+T cells, CD8+T cells and memory CD8+T cells (c) among vaccinated group against ancestral and BA.5 strain from T1 timepoint versus T0 timepoint. **(d-f)** Fold change of of serum anti-spike IgG and IgA (a) and B cells, memoryB cells, Tfh and memory Tfh cells (b), CD4+T cells, memory CD4+T cells, CD8+T cells and memory CD8+T cells (c) among vaccinated group against ancestral and BA.5 strain from T2 timepoint versus T0 timepoint. Fold change of of serum anti-spike IgG and IgA (a) and B cells, memoryB cells, Tfh and memory Tfh cells (b), CD4+T cells, memory CD4+T cells, CD8+T cells and memory CD8+T cells (c) among vaccinated group against ancestral and BA.5 strain from T1 timepoint versus T0 timepoint. Data are shown as the fold-change between T0, T1, and T2 in vaccinated group. Wilcoxon matched-pairs signed rank test was performed for paired data. \* indicates  $p < 0.05$ , \*\* indicates  $p < 0.01$ , \*\*\* indicates  $p < 0.001$ , \*\*\*\* indicates  $p < 0.0001$ . ns indicates no significant difference.

Figure 6




Figure 6

**Distinct patterns of immune trajectories in breakthrough infected individuals versus natural infected donors. (a)** A cold-to-hot Heatmap and hierarchical clustering represents the scaled magnitude of SARS-CoV-2 specific humoral, mucosal and cellular immune responses including spike binding antibody, neutralization activities, Fc-mediated effector function, cellular responses, at T1 timepoint after BA.5 infection between vaccinated versus unvaccinated group. Each column represents a vaccinated or

unvaccinated individuals, while each role represents an immune parameter. The distribution of markers and participants in the cohort was automatically performed by supervised hierarchical clustering. **(b)** A Least Absolute Shrinkage Selection Operator (LASSO) was used to select antibody features that contributed most of the discriminate vaccinated versus unvaccinated individuals. A partial least square discriminant analysis (PLSDA) was used to visualize samples. LASSO selected features were ranked based on their Variable of Importance (VIP) score, and the loadings of the latent variable 1 (LV1) were visualized in a bar graph. **(c)** Selected immune parameter features were ordered according to their variable importance in projection (VIP) score. **(d-e)** Correlation analysis between the parameters of adaptive immune responses, including binding antibody, neutralization activities, B cell, CD4 cell, CD8 cell, Tfh cell responses as well as their memory subsets at T1 timepoint after BA.5 infection in vaccinated **(d)** versus unvaccinated donors **(e)**. **(f-g)** Correlation analysis of mucosal antibody response and serum neutralization activity in vaccinated individuals **(f)** versus unvaccinated **(g)** donors. The strength of a correlation (Sperman's correlation coefficient) is demonstrated by color of square, the significance is indicated by asterisks. Correlation between 2 continuous variables was analyzed using the spearman correlation analysis. \* indicates  $p < 0.05$ , \*\* indicates  $p < 0.01$ , \*\*\* indicates  $p < 0.001$ , \*\*\*\* indicates  $p < 0.0001$ . ns indicates no significant difference.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarymaterialsandmethods.docx](#)
- [Supplementaryfigures.docx](#)